Overview

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

Status:
Completed
Trial end date:
2016-08-09
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the safety and efficacy of new ophthalmic formulations of bimatoprost in patients with open angle glaucoma and ocular hypertension. At least 3 dose strengths will be evaluated based on internal data review of each cohort. The study was planned to be conducted in 2 stages. Stage 1 was an open-label and Stage 2 was planned to be masked; however only Stage 1 was conducted.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost
Latanoprost
Ophthalmic Solutions
Pharmaceutical Solutions
Timolol
Criteria
Inclusion Criteria:

- Diagnosis of open angle glaucoma or ocular hypertension

Exclusion Criteria:

- Uncontrolled medical conditions

- Anticipated wearing of contact lenses during the study